ASCO: Significant Survival Benefits For Iza-Bren In 2L TNBC/ESCC But Safety Issues Remain
Iza-bren demonstrated statistically significant and clinically meaningful improvements in overall and progression-free survival in second- and later-line TNBC and second-line ESCC, but a higher proportion of dose reductions due to adverse events.
Scrip - June 3, 2026

‘Building From A Strong Foundation’: Merck Lays Out Oncology Vision At ASCO
Under pressure as its top seller Keytruda nears the end of its exclusivity, Merck & Co. execs used an analyst briefing at ASCO to make the case that the company is ready to deliver on a new generation of oncology blockbusters.
Scrip - June 3, 2026

EOFlow Clears Path To US Market After Court Wipes Out Insulet’s $59M Verdict
The Federal Circuit Court of Appeals has reversed Insulet’s $59m intellectual property verdict against EOFlow, leaving Insulet weighing its options while EOFlow prepares for a US launch. The appeals court found that Insulet brought its claims too long after learning of the alleged infringement.
Medtech Insight - June 2, 2026

Revised US FDA Payor Communications Guidance Codifies Unapproved Uses Safe Harbor
An updated draft guidance incorporates statutory changes allowing drug and device manufacturers to share truthful information with payors about unapproved products and uses, and extends health care economic information provisions to devices.
Medtech Insight - June 2, 2026

Medtech Sweden: Inside Gothenburg’s GoCo, A House And City Built For Innovation
This article, the second drawn from a media event hosted by the City of Gothenburg, spotlights a visit to GoCo House Health Innovation City, a life-science district where over 100 companies, research institutions and academic partners share labs and offices adjacent to AstraZeneca’s R&D hub.
Medtech Insight - June 2, 2026

The AI Reading 1,000-Page Cancer Records Before Your Doctor Does
Triomics has raised $22m and deployed its clinical trial matching platform at four of the country’s top cancer centers. Its CEO says the hardest problem wasn’t the technology – it was convincing physicians the machine could reason.
Medtech Insight - June 2, 2026

GRAIL’s Galleri Cleared Secondary Bars At ASCO, But Primary Endpoint Miss Remains
Galleri met multiple secondary endpoints at ASCO 2026. Still, the NHS-Galleri trial's failure to hit its primary combined Stage III/IV endpoint leaves FDA reviewers and payers weighing compelling secondary data against a key statistical shortfall.
Medtech Insight - June 2, 2026

Estee Lauder Says Price Tanked Puig Deal, Unilever Unveils US Innovation Centre; Beauty Biz Roundup
Estee Lauder CEO Stéphane de La Faverie says while a Puig deal made sense strategically, it didn’t work financially. Separately, Unilever plans to open a US innovation centre in New Haven, Conn. and IFF agrees to divest its Food Ingredients business.
HBW Insight - June 2, 2026

FTC’s Second Recent Target Of Children’s Supplement Claims Could Test Its MLM Oversight
FTC complaints alleges Amare Global Holdings violated advertising regulations by claiming without substantiation that products including Happy Juice, Kids Mood+ and Kids Happy Juice will lower, reduce or regulate cortisol and cure or treat depression, anxiety and ADHD.
HBW Insight - June 2, 2026

Church & Dwight Waves History Flag Behind Boosting Arm & Hammer Brand Sales
“The US is celebrating its 250-year anniversary. Church & Dwight's 180 years,” says CEO Richard Dierker. Arm & Hammer brand awareness is in the “mid- to high-90s” and “rivals almost any other brand that you know.”
HBW Insight - June 2, 2026

Hikma Invests $267m In Ohio Facility Expansion
Hikma has revealed an investment of more than a quarter of a billion dollars in its Bedford and Columbus facilities in Ohio, delivering on a commitment it made last year to spend a full billion over the next five years to further expand its US manufacturing base.
Generics Bulletin - June 2, 2026

Outlook Eyes Rapid FDA Approval For Ophthalmic Bevacizumab With Refiled BLA
Outlook Therapeutics has once again resubmitted its filing for its bevacizumab-based Lytenava ophthalmology treatment to the FDA, following the favorable outcome of a recent dispute resolution process. A PDUFA date and decision are expected within 60 days.
Generics Bulletin - June 2, 2026

Apotex Aims For Over C$1bn As It Launches IPO
Apotex has revealed financial details of its recently-announced IPO, with the Canadian generics and biosimilars giant seeking proceeds of more than C$1bn in a move that would value the firm at more than C$5bn.
Generics Bulletin - June 2, 2026

Celltrion Uses Canada To Crack Open Cosentyx Market
Celltrion’s Canadian filing for CT-P55 looks to give it an early route into North America’s major Cosentyx biosimilar opportunity, as Western rivals remain absent and Asian developers define the field.
Generics Bulletin - June 2, 2026

Podcast: Jeremy Levin’s Call to Action to Save American Biotech
Jeremy Levin, an industry veteran and author of a new book, argues that biotech must defend scientific integrity, attract long-term capital, and rebuild public trust. Otherwise, it risks ceding America's innovation primacy to global competitors.
In Vivo - June 2, 2026

PCOS Renamed PMOS: What The Reclassification Means For Drug Development And Market Access
The global consensus reclassifying polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome (PMOS) is opening new fronts in drug development, at-home diagnostics, and chronic disease management.
In Vivo - June 2, 2026